Emergence of pristinamycin resistance in India

Quinupristin and dalfopristin combination has been advocated as a drug of choice for multi-drug resistant (MDR) gram-positive cocci (GPC). We are reporting two cases of neonatal septicemia, caused by the methicillin resistant Staphylococcus aureus (MRSA), showing primary in vitro pristinamycin resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Keshari, Shyam Sunder, Kapoor, Arun Kumar, Kastury, Nira, Singh, Dharmendra Kumar, Bhargava, Anudita
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825015/
https://www.ncbi.nlm.nih.gov/pubmed/20177582
http://dx.doi.org/10.4103/0253-7613.48884
Descripción
Sumario:Quinupristin and dalfopristin combination has been advocated as a drug of choice for multi-drug resistant (MDR) gram-positive cocci (GPC). We are reporting two cases of neonatal septicemia, caused by the methicillin resistant Staphylococcus aureus (MRSA), showing primary in vitro pristinamycin resistance. The Minimum inhibitory concentrations (MIC) for pristinamycin in these two cases were 30 μg and 25 μg, respectively. Universal advocacy of pristinamycin for the therapy of MDR GPC infections should be re-evaluated.

Ejemplares similares